11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?
about
Something old, something new and something very old: drugs for treating type 2 diabetesThe Metabolic Implications of Glucocorticoids in a High-Fat Diet Setting and the Counter-Effects of ExerciseZataria multiflora increases insulin sensitivity and PPARγ gene expression in high fructose fed insulin resistant ratsNovel and emerging diabetes mellitus drug therapies for the type 2 diabetes patientDiscovery of Novel Insulin Sensitizers: Promising Approaches and Targets.Formation of threohydrobupropion from bupropion is dependent on 11β-hydroxysteroid dehydrogenase 1.11β-hydroxysteroid dehydrogenase types 1 and 2 activity in subcutaneous adipose tissue in humans: implications in obesity and diabetes.Antimicrobial and hypoglycemic activities of novel N-Mannich bases derived from 5-(1-adamantyl)-4-substituted-1,2,4-triazoline-3-thionesGlucocorticoids and type 2 diabetes: from physiology to pathologyTrigonella foenum-graecum water extract improves insulin sensitivity and stimulates PPAR and γ gene expression in high fructose-fed insulin-resistant rats.Peripheral targets in obesity treatment: a comprehensive update.Novel therapeutics for type 2 diabetes: insulin resistance.Complex association between body weight and fracture risk in postmenopausal women.Adamantane-Isothiourea Hybrid Derivatives: Synthesis, Characterization, In Vitro Antimicrobial, and In Vivo Hypoglycemic Activities.Unfolding Novel Mechanisms of Polyphenol Flavonoids for Better Glycaemic Control: Targeting Pancreatic Islet Amyloid Polypeptide (IAPP).Hepatic 11β-hydroxysteroid dehydrogenase type 1 activity in obesity and type 2 diabetes using a novel triple tracer cortisol technique.The Hepato-Hypothalamic-Pituitary-Adrenal-Renal Axis: Mathematical Modeling of Cortisol's Production, Metabolism, and Seasonal Variation.Protostane-Type Triterpenoids from Alisma orientale.Emerging approaches for the treatment of hypertriglyceridemia.An inhibitor of 11-β hydroxysteroid dehydrogenase type 1 (PF915275) alleviates nonylphenol-induced hyperadrenalism and adiposity in rat and human cells.
P2860
Q26865663-0B681B79-291E-48D1-AC7E-F895A1BECA45Q28076700-A930587E-3FED-4DA2-8BB5-E34A0E5FCEFFQ33713953-77E7766B-A287-4F8B-92D9-A0F2CA7274ABQ33759570-70B4765A-3752-423F-BD6F-5F40CCDDDF70Q33808884-714669A0-FA2A-4B3B-AB09-A26DDCC0DF8FQ34353804-296CA9D1-6252-4C48-8559-4D5DB5662FFDQ34810875-3AABE723-0E58-4404-84D6-034BA7014B89Q34835155-3F7D117E-1B69-42D8-9BD0-AC70E7E89733Q36506631-151A8523-A884-477E-B0B0-B0A9F6CA28F0Q36755710-752881E7-3518-401C-A106-ECAE6ED34796Q38194649-4C1918E9-8CD9-4B20-8B2C-676E0366B1FCQ38259507-7D7DE378-DFE7-4540-8292-434A64980537Q38317545-20DC2A2B-466A-40C1-81DA-7429CCCF6695Q38806728-B0D5A837-E6C9-4CAD-97D4-5459193FD6E3Q41195653-7768DF69-64DB-4BB6-B99A-260A45DD48A8Q41691890-374426CF-A78D-4F4D-A414-A82BD53D03FAQ47634067-40C3966D-37B8-49D0-9958-E49004DB3CD1Q50010655-47633A74-C23E-4B8E-8803-31BE03E7BE64Q51334679-56789111-C7DE-47E5-94BE-F633C41D3740Q55715253-586DEAEF-B680-48D4-92CE-12FFA666C107
P2860
11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
11beta-Hydroxysteroid dehydrog ...... and obesity-related disorders?
@en
type
label
11beta-Hydroxysteroid dehydrog ...... and obesity-related disorders?
@en
prefLabel
11beta-Hydroxysteroid dehydrog ...... and obesity-related disorders?
@en
P2093
P1433
P1476
11beta-Hydroxysteroid dehydrog ...... and obesity-related disorders?
@en
P2093
Asterios Karagiannis
Fotini Adamidou
Marina Kita
Niki Katsiki
Panagiotis Anagnostis
P356
10.1016/J.METABOL.2012.05.002
P577
2012-05-30T00:00:00Z